Slide 1: Fourth Quarter and Fiscal Year 2009 Conference Call
Exhibit 99.1 Simulations Plus, Inc. NASDAQ: SLP Fourth Quarter and Fiscal Year 2009 Conference Call November 30, 2009
Slide 2: Introduction and Welcome
Introduction and Welcome • Introduction and Welcome • Agenda – Fourth Quarter FY 2009 (4QFY09) Financial Summary – Fiscal year 2009 Financial Summary – Progress in Business Units – Strategy Going Forward – Questions and Answers
Slide 3: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 4: 4QFY09 (3 months) Financial Summary
4QFY09 (3 months) Financial Summary • Gross revenues = $1.839 MM (up 0.2% from 4QFY08) – Pharmaceutical software and services = $1.107 MM (up 1.4% from $1.092 MM in 4QFY08) – Words+ subsidiary = $732,000 (down 1.5% from $744,000 4QFY08) • SG&A = $966,000 (down 2.8% from $995,000 in 4QFY08) – SG&A de
Slide 5: FY09 (12 months) Financial Summary
FY09 (12 months) Financial Summary • Gross revenues = $9.143 MM (up 2.0% from $8.968 MM in FY08) – Pharmaceutical software and services = $6. 031 MM (up 4.1% from $6.055 MM in FY08) – Words+ subsidiary = $2.842 MM (down 2.4% from $2.912 MM in FY08) • SG&A = $3.896 MM (up 5.3% from $3.699 MM in FY08)
Slide 6: Share Repurchase Program
Share Repurchase Program • Board of directors authorized share repurchase program for up to $2.5 million from October 2008 through October 2009. Actually repurchases began December 2, 2008, so the board extended the repurchase period through December 1, 2009. • As of November 27, over 1.02 MM shares
Slide 7: Progress - ADMET Predictor
Progress - - 1 • ADMET Predictor™ (Structure-property prediction program) – Version 4.0 was released in July – New Dose Optimization Module estimates dose amount needed for new molecules based on mini-GastroPlus simulation • Developed under Pfizer funding and in active use at Pfizer now – New toxici
Slide 8: Solubility in Biorelevant Fluids
Solubility in Biorelevant Fluids • During FY09 we funded a series of experiments with Northeastern University to measure the solubility of 160 drugs and drug-like compounds in three different types of biorelevant fluids: – Fasted state simulated gastric fluid (FaSGF) – Fasted state simulated intesti
Slide 9: Progress - ClassPharmer
Progress - - 2 • ClassPharmer™ (Data Mining and De Novo Molecule Design) – Numerous improvements were being incorporated during the 4th quarter, and Version 4.7 was released in October. – We continue to enhance ClassPharmer’s capabilities in data mining and de novo molecule design (design of new mol
Slide 10: Progress - DDDPlus
Progress - - 3 DDDPlus - Simulates laboratory dissolution experiments Sales continue to increase steadily Version 3.0 was released in Q3 with a number of important enhancements Remains the only tool of its kind
Slide 11: Progress - GastroPlus
Progress - - 4 • GastroPlus™ – Development of Drug-drug Interaction module continues under funded collaboration with Roche - initial capability in use at Roche – Development of ocular delivery capability under a funded collaboration with Pfizer is nearly complete – Development of a nasal-pulmonary d
Slide 12: GastroPlus Ocular Delivery - Funded Collaboration
GastroPlus Ocular Delivery - Funded Collaboration
Slide 13: GastroPlus Pulmonary Delivery
GastroPlus Pulmonary Delivery
Slide 14: Progress - Words+ subsidiary
Progress - - 5 • Words+ subsidiary – General economy appears to be affecting this business - many states are struggling, and a large percentage of our sales come from 3rd-party sources (Medicaid, Medicare, schools, state vocational rehabilitation programs, etc.) – New Conversa™ communication device
Slide 15: Miscellaneous Items
Miscellaneous Items • Potential acquisition we were working on for a number of months did not go through - - seller decided to go with another buyer. Potential remains to acquire software part of the business, which was our primary interest. • Due diligence currently in progress on three acquisition
Slide 16: Strategy Going Forward
Strategy Going Forward • Continue to expand product line and services – Pharmaceutical software and services • Continue to expand Life Sciences team – For new product development as identified in corporate strategic planning – To increase capacity to conduct consulting studies and funded collaborati
Slide 17: Summary
Summary • Simulations Plus financial strength continues – Excellent cash position that continues to grow in spite of spending over $1 million on share repurchases - cash increased – No debt – Share repurchase has reduced number of shares outstanding by over 1 million shares • Decent fourth quarter -
Slide 18: Additional Factors
Additional Factors • State of the pharmaceutical industry – Mergers have had no effect on business to date - in fact licenses have increased at the larger companies. Academic and government licenses have also increased. – Large companies continue to adopt in silico (software) technologies in various
Slide 19: Questions?
Questions? simulations plus, inc. @&
Slide 20: Slide 20